The anti-hCTLA4 isotype family features the variable region of ipilimumab. Ipilimumab is a fully human IgG1 monoclonal antibody that targets CTLA-4 (also known as CD152), a negative regulator of T cell activation. By binding CTLA-4, ipilimumab inhibits negative signals that physiologically downregulate T cell activation and exerts its therapeutic activity by upregulating the antitumor activity of T lymphocytes. In addition, Ipilimumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) and TNF-a production. Ipilimumab has been approved by the FDA for the treatment of unresectable or metastatic melanoma. Ipilimumab is undergoing clinical trials for other types of cancers, including lung cancer.
InvivoGen's Anti-hCTLA4 isotype family has been generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography with protein G (IgG) or peptide M (IgA2).
